Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FJUZ3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,167
Award facts
- Contract value 100% obligated
- $13,167.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $13,167 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA PEN 30 MG/ML. The award, issued February 4, 2026, with an ultimate completion date of February 5, 2026, carries no set-aside designation, indicating the vendor competed in an unrestricted procurement environment. This delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion governmentwide acquisition strategy designed to streamline pharmaceutical supply chains for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program with a ceiling value of $499,999,999 through December 31, 2036, positioning the vendor as a critical regional pharmaceutical supplier for military medical operations. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals supporting diverse therapeutic needs across the federal military healthcare system. This delivery order for FASENRA, a biologic medication, exemplifies the vendor's role in fulfilling specialized pharmaceutical requirements under the broader prime vendor contract framework.
Quick answers
Who was awarded contract SPE2DR26FJUZ3?
SPE2DR26FJUZ3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FJUZ3 worth?
The government has obligated $13,167 on SPE2DR26FJUZ3.
Is contract SPE2DR26FJUZ3 an order under another contract?
Yes. SPE2DR26FJUZ3 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUZ3 competed?
The extent of competition for SPE2DR26FJUZ3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award